2025 was a year characterised by a clear focus on clinical system optimisation and regulatory preparations. Disciplined cost control and prioritised resource allocation strengthened the company’s financial resilience, without compromising delivery. During the fourth quarter, clinical preparations for the next phase of the clinical programme were completed, enabling the Proof of Concept study to commence in January 2026.
“We have now reached the point where our technology is being applied in a structured clinical setting. Through a controlled, high-quality and resource-efficient execution, we are building both clinical value and a commercial foundation for NanoEcho’s continued development,” comments Linda Persson, CEO of NanoEcho.
Subsequent to the end of the reporting period, the Board resolved to carry out a rights issue. Work on the application for EUR 2.5 million in grant funding through the EU’s EIC Accelerator programme is ongoing. Positive feedback has been received in the initial stage of the process, and the next phase of the application procedure is now underway.
Read the full year-end report here!
Watch Linda summarise the period!